Thomas O. Crawford, Kathryn J. Swoboda, Darryl C. De Vivo, Enrico Bertini, Wuh‐Liang Hwu, Richard S. Finkel, Janbernd Kirschner, Nancy L. Kuntz, Aledie Navas Nazario, Julie A. Parsons, Astrid Pechmann, Monique M. Ryan, Russell J. Butterfield, Haluk Topaloglu, Tawfeg Ben‐Omran, Valeria A. Sansone, Yuh‐Jyh Jong, Francy Shu, Cong Zhu, Stephanie Raynaud, Tiffany R. Lago, Angela D. Paradis, Richard Foster, Russell Chin, Zdenek Berger,

Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy

  • Physiology (medical)
  • Cellular and Molecular Neuroscience
  • Neurology (clinical)
  • Physiology
Save to CiteDrive Show PDF

AbstractIntroduction/AimsNURTURE (NCT02386553) is an open‐label study of nusinersen in children (twoSMN2copies,n = 15; threeSMN2copies,n = 10) who initiated treatment in the presymptomatic stage of spinal muscular atrophy (SMA). A prior analysis after ~3 y showed benefits on survival, respiratory outcomes, motor milestone achievement, and a favorable safety profile. An additional 2 y of follow‐up (data cut: February 15, 2021) are reported.MethodsThe primary endpoint is time to death or respiratory intervention (≥6 h/day continuously for ≥7 days or tracheostomy). Secondary outcomes include overall survival, motor function, and safety.ResultsMedian age of children was 4.9 (3.8–5.5) y at last visit. No children have discontinued the study or treatment. All were alive. No additional children utilized respiratory intervention (defined per primary endpoint) since the prior data cut. Children with threeSMN2copies achieved all World Health Organization (WHO) motor milestones, with all but one milestone in one child within normal developmental timeframes. All 15 children with twoSMN2copies achieved sitting without support, 14/15 walking with assistance, and 13/15 walking alone. Mean Hammersmith Functional Motor Scale Expanded total scores showed continued improvement. Subgroups with twoSMN2copies, minimum baseline compound muscle action potential amplitude ≥2 mV, and no baseline areflexia had better motor and nonmotor outcomes versus all children with twoSMN2copies.DiscussionThese results demonstrate the value of early treatment, durability of treatment effect, and favorable safety profile after ~5 y of nusinersen treatment. Inclusion/exclusion criteria and baseline characteristics should be considered when interpreting presymptomatic SMA trial data.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive